Carolinas Medical Center
Charlotte, North Carolina, 28203, United States
NCT Number: NCT00823108
The purpose of this study is to determine if a glucose-insulin-potassium (GIK) solution can be safely administered to patients with septic shock. GIK has been used in thousands of critically ill patients in research studies with very few safety concerns. However, there is a lack of data in regards to patients with septic shock. There are many reasons to believe that GIK would be beneficial in sepsis, including improving heart function and decreasing inflammation. This study will administer intravenous GIK for 12 hours continuously and monitor 10 subjects for 24 hours. A control arm will be used and 10 patients will receive the same monitoring but will not receive GIK.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Charlotte, North Carolina, 28203, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
12 hour infusion of GIK solution
Time frame: During infusion
Time frame: During infusion
Wake Forest University Health Sciences
Other
Rapid Administration of Insulin in Sepsis: A Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07658014
Cardiovascular Diseases, Infections
Querétaro City, Querétaro, Mexico
View Trial DetailsNCT05900284
Acute Kidney Injury, Female Urogenital Diseases
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT02361528
Infections, Inflammation
Amiens, France
View Trial DetailsNCT05194189
Infections, Inflammation
Guanzhou, Guangdong, China
View Trial Details